Andersons pediatric cardiology 1670
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.55 KB, 3 trang )
Cardiologicabnormalitiesinnoonansyndrome:
phenotypicdiagnosisandechocardiographic
assessmentof118patients.JAmCollCardiol.
1993;22(4):1189–1192.
102.SznajerY,KerenB,BaumannC,etal.The
spectrumofcardiacanomaliesinnoonan
syndromeasaresultofmutationsinthePTPN11
gene.Pediatrics.2007;119(6):e1325–e1331.
103.ColquittJL,NoonanJA.Cardiacfindingsin
noonansyndromeonlong-termfollow-up.
CongenitHeartDis.2014;9(2):144–150.
104.ShawAC,KalidasK,CrosbyAH,JefferyS,
PattonMA.Thenaturalhistoryofnoonan
syndrome:along-termfollow-upstudy.Arch
DisChild.2007;92(2):128–132.
105.HickeyEJ,MehtaR,ElmiM,etal.Survival
implications:hypertrophiccardiomyopathyin
noonansyndrome.CongenitHeartDis.
2011;6(1):41–47.
106.KouzK,LissewskiC,SprangerS,etal.
Genotypeandphenotypeinpatientswithnoonan
syndromeandaRIT1mutation.GenetMed.
2016;18(12):1226–1234.
107.JhangWK,ChoiJH,LeeBH,KimGH,Yoo
HW.Cardiacmanifestationsandassociations
withgenemutationsinpatientsdiagnosedwith
RASopathies.PediatrCardiol.
2016;37(8):1539–1547.
108.TartagliaM,KalidasK,ShawA,etal.PTPN11
mutationsinnoonansyndrome:molecular
spectrum,genotype-phenotypecorrelation,and
phenotypicheterogeneity.AmJHumGenet.
2002;70(6):1555–1563.
109.LeeBH,KimJM,JinHY,etal.Spectrumof
mutationsinnoonansyndromeandtheir
correlationwithphenotypes.JPediatr.
2011;159(6):1029–1035.
110.LepriF,DeLucaA,StellaL,etal.SOS1
mutationsinnoonansyndrome:molecular
spectrum,structuralinsightsonpathogenic
effects,andgenotype-phenotypecorrelations.
HumMutat.2011;32(7):760–772.
111.PoteruchaJT,JohnsonJN,O'LearyPW,etal.
Surgicalventricularseptalmyectomyfor
patientswithnoonansyndromeandsymptomatic
leftventricularoutflowtractobstruction.AmJ
Cardiol.2015;116(7):1116–1121.
112.HahnA,LauriolJ,ThulJ,etal.Rapidly
progressivehypertrophiccardiomyopathyinan
infantwithnoonansyndromewithmultiple
lentigines:palliativetreatmentwitharapamycin
analog.AmJMedGenetA.2015;167A(4):744–
751.
113.YiJS,HuangY,KwaczalaAT,etal.Low-dose
dasatinibrescuescardiacfunctioninnoonan
syndrome.JCIinsight.2016;1(20):e90220.
114.WuX,SimpsonJ,HongJH,etal.MEK-ERK
pathwaymodulationamelioratesdisease
phenotypesinamousemodelofnoonan
syndromeassociatedwiththeraf1(L613V)
mutation.JClinInvest.2011;121(3):1009–1025.
115.NakamuraT,ColbertM,KrenzM,etal.
MediatingERK1/2signalingrescuescongenital
heartdefectsinamousemodelofnoonan
syndrome.JClinInvest.2007;117(8):2123–
2132.
116.MarinTM,KeithK,DaviesB,etal.Rapamycin
reverseshypertrophiccardiomyopathyina
mousemodelofLEOPARDsyndromeassociatedPTPN11mutation.JClinInvest.
2011;121(3):1026–1043.
117.GrippKW,HopkinsE,Sol-ChurchK,etal.
Phenotypicanalysisofindividualswithcostello
syndromeduetoHRASp.g13c.AmJMed
GenetA.2011;155A(4):706–716.
118.LinAE,AlexanderME,ColanSD,etal.
Clinical,pathological,andmolecularanalysesof
cardiovascularabnormalitiesincostello
syndrome:aRas/MAPKpathwaysyndrome.Am
JMedGenetA.2011;155A(3):486–507.
119.AbeY,AokiY,KuriyamaS,etal.Prevalence
